{
    "nctId": "NCT04159142",
    "briefTitle": "Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer",
    "officialTitle": "Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple Negative Breast Cancer, Nab-paclitaxel",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 414,
    "primaryOutcomeMeasure": "Progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Females with age between 18 to 70 years old;\n2. Histologically confirmed triple negative breast cancer;\n3. No more than one-line prior treatment for locally advanced or metastatic breast cancer;\n4. Have at least one measurable lesion as per the RECIST criteria (version 1.1);\n5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one;\n6. Patients with life expectancy of at least 3 months;\n7. Bone marrow function\uff1aneutrophils (\u22651.5\u00d710\\^9/L), platelets (\u2265100\u00d710\\^9/L), hemoglobin (\u226590 g/L);\n8. Renal and hepatic function: Serum creatinine\u2264 1.5\u00d7institutional upper limit of normal (ULN); AST and ALT \u2264 2.5 \u00d7 ULN; Total bilirubin\u22641.5\u00d7ULN, or patients with Gilbert's syndrome \u2264 2.5 \u00d7 ULN;\n9. Patients had good compliance with the planned treatment, understood the research process and written informed consent.\n\nExclusion Criteria:\n\n1. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores;\n2. Brain metastasis;\n3. Recurrence or metastasis within 6 months after capecitabine withdrawal;\n4. Recurrence or metastasis within 6 months after platinum withdrawal;\n5. Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months;\n6. Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding;\n7. Patients who had Grade 2 or above Peripheral neuropathy;\n8. Patients with severe systemic infection or other serious diseases;\n9. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;\n10. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;\n11. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial;\n12. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given;\n13. The researchers considered the patients who were not suitable for enrollment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}